Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : For entities : Novartis ag save search
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
Published: 2024-04-24 (Crawled : 05:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
malaria positive treatment for novartis
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Published: 2024-04-23 (Crawled : 18:00) - globenewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 1.69%
H: 0.02%
C: -0.74%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 4.32%
H: 0.0%
C: 0.0%
lutathera fda first approved tumors for novartis therapy
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Published: 2024-04-15 (Crawled : 18:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
fabhalta nephropathy for novartis show
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.32%
H: 0.04%
C: -0.56%
ARVN | $32.51 -4.38% -4.58% 470K
|
Health Technology
|
| O: 8.28%
H: 0.56%
C: -4.75%
arv-766 protac license cancer treatment global protein for commercialization agreement
Novartis tender offer for MorphoSys AG commences
Published: 2024-04-11 (Crawled : 09:00) - globenewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: -0.32%
H: 0.48%
C: -0.17%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.32%
H: 0.04%
C: -0.56%
MOR | News | $18.07 0.17% 0.17% 130K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: -0.39%
for novartis
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.